Nissan Chemical Industries Limited

Yukihiro Shigeta

Kazufumi Yanagihara

Toru Yamashita

Kazuhiko Ohrai

Norihisa Ishiwata

Yutaka Hirokawa

Toru Tsukagoshi

Katsuaki Miyaji

Keizo Tanikawa

Shunsuke Iwamoto

Hirofumi Ota

Satoshi Nakano

Masato Horikawa

Shingo Owada

Yoshio Ohara

Takanori Nakamura

Tsuneo Watanabe

Junji Kamon

Masayuki Sato

Shingo Umezawa

Koji Toyama

Kazuya Takeuchi

Yusuke Shintani

Hiroshi Nagai

Shunuske Iwamoto

Kei Nagae

Megumi Io

Katsuaki Myaji

Shingo Oowada

Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein Ris an aryl group fused to a saturated ring or the like, A, B, L, R, L, L, Y, L, Rand X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof. 

Fused heterocyclic compounds and thrombopoietin receptor activators

A compound represented by the formula (1): wherein A, B, R, L, R, L, L, Y, L, Rand X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators

Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases. 

Pyridazinone compounds and P2X7 receptor inhibitors

The present invention provides compounds useful for prevention, treatment or alleviation of diseases against which activation of the thrombopoietin receptor is effective. A compound represented by the formula (1): wherein A, B, R, L, R, L, L, Y, L, Rand X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Amide compound and thrombopoietin receptor activator

Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R, R, R, L, L, L, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators

Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R, R, R, L, L, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Hydrazide compounds and thrombopoietin receptor activators

A compound represented by the formula (I) (wherein R, R, Rand Rare as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Thiophene compounds and thrombopoietin receptor activators

This invention relates to benzopyran derivatives of the formula (1) or the formula (2) wherein Rand Rrepresent independently of each other hydrogen atom or Calkyl group, Rrepresents hydroxyl group or Calkylcarbonyloxy group, Rrepresents hydrogen atom or Calkyl group, Rrepresents Calkyl group substituted with Caryl group or heteroaryl group, Rrepresents Calkyl group, Calkoxy group, halogen atom, nitro group, C(O)NH, C(O)NHRor C(O)NRR, or pharmaceutically acceptable salts thereof. These compounds are useful as an antiarrhythmic agent 

Substituted benzopyran derivatives against arrhythmia

This invention relates to benzopyran derivatives of the formula (I) wherein, R and R represent each independently a C alkyl group, etc, R represents a hydroxyl group, etc, R represents a hydrogen atom, etc, R represents a hydrogen atom, R represents a hydrogen atom, etc, X is absent, or represents C&boxH;O, etc, R represents a hydrogen atom, a C alkyl group, etc, R represents a hydrogen atom or a nitro group, when R represents a nitro group, Y represents a C alkylene group, &mdash;(CH ) &mdash;CR R &mdash;(CH ) &mdash; or &mdash;(CH ) &mdash;O&mdash;(CH ) &mdash;, R represents a hydrogen atom, an amino group, a C alkoxy group, a C alkylthio group, a C alkylamino group, a C alkoxycarbonylamino group, etc, or pharmaceutically acceptable salts thereof. These compounds are useful as an antiarrhythmic agent.

4-aminobenzopyran derivatives

This invention relates to a 4-oxybenzopyran derivative of formula (I) wherein, R and R represent each independently a hydrogen atom, a C alkyl group or a phenyl group; R represents a hydroxyl group or C alkylcarbonyloxy group; R represents a hydrogen atom, a C cycloalkyl group, a C alkyl group, a C alkylcarbonyl group, a C alkylaminocarbonyl group, a di-C alkylaminocarbonyl group, an aryl group or a heteroaryl group; R represents a hydrogen atom or a C alkyl group; X is absent or represents C&boxH;O or SO ; R represents a hydrogen atom, a C alkyl group or a C cycloalkyl group; R represents a hydrogen atom, a halogen atom, a nitro group or a cyano group; or a pharmaceutically acceptable salt thereof. And this invention also relates to a drug for treating arrhytmia having the prolongation effect on the functional refractory period comprising said compound or a pharmaceutically acceptable salt thereof as an active ingredient.

4-oxybenzopyran derivative

Benzopyran derivative

This invention relates to a 4-oxybenzopyran derivative of formula (I) wherein, R and R represent each independently a hydrogen atom, a C alkyl group or a phenyl group; R represents a hydroxyl group or a C alkylcarbonyloxy group; R represents a hydrogen atom, a C cycloalkyl group, a C alkyl group, a C alkylcarbonyl group, a C alkylaminocarbonyl group, a di-C alkylaminocarbonyl group, an aryl group or a heteroaryl group; n represents an integer of 0-4; X represents &mdash;C(&boxH;O)NR &mdash;, &mdash;NR &mdash;, &mdash;NHC(&boxH;O)NH&mdash; or &mdash;S(O) NH&mdash;; R5 represents a hydrogen atom or (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), or (l); R represents a hydrogen atom, a halogen atom, a nitro group or a cyano group; or a pharmaceutically acceptable salt thereof. And this invention also relates to an antiarrhythmic agent having the prolongation effect of the functional refractory period comprising said compound or a pharmaceutically acceptable salt thereof as an active ingredient.

Growing community of inventors

Funabashi, Japan

Yukihiro Shigeta